- Home
- ADTX vs PRFX Comparison
ADTX vs PRFX Comparison
Compare ADTX & PRFX Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
Company Overview
Basic Information| Metric | ADTX | PRFX |
|---|---|---|
| Founded | 2017 | 2007 |
| Country | United States | Israel |
| Employees | N/A | N/A |
| Industry | Biotechnology: Pharmaceutical Preparations | Biotechnology: Pharmaceutical Preparations |
| Sector | Health Care | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 2.1M | 1.8M |
| IPO Year | 2020 | 2020 |
Fundamental Metrics
Financial Performance| Metric | ADTX | PRFX |
|---|---|---|
| Price | $1.26 | $0.88 |
| Analyst Decision | | |
| Analyst Count | 0 | 0 |
| Target Price | N/A | N/A |
| AVG Volume (30 Days) | ★ 3.9M | 147.3K |
| Earning Date | 11-18-2025 | 03-03-2026 |
| Dividend Yield | N/A | N/A |
| EPS Growth | N/A | N/A |
| EPS | N/A | ★ N/A |
| Revenue | ★ $5,945.00 | N/A |
| Revenue This Year | $15,768.94 | N/A |
| Revenue Next Year | N/A | N/A |
| P/E Ratio | N/A | N/A |
| Revenue Growth | N/A | ★ N/A |
| 52 Week Low | $1.30 | $0.80 |
| 52 Week High | $8,633.16 | $16.63 |
Technical Indicators
Market Signals| Indicator | ADTX | PRFX |
|---|---|---|
| Relative Strength Index (RSI) | 37.25 | 42.38 |
| Support Level | $1.30 | $0.85 |
| Resistance Level | $2.20 | $1.00 |
| Average True Range (ATR) | 0.54 | 0.10 |
| MACD | -0.23 | 0.01 |
| Stochastic Oscillator | 1.58 | 9.82 |
Price Performance
Historical ComparisonAbout ADTX Aditxt Inc.
Aditxt Inc is a life sciences company that develops, builds, and grows innovations with a focus on monitoring and modulating the immune system. It develops products designed to induce tolerance to transplanted organs. Its portfolio consists of two programs Adimune and AditxtScore. It firm's immunosuppressive (anti-rejection) drugs have made possible life-saving organ transplantation procedures and blocking of unwanted immune responses in autoimmune diseases. It is also developing a technology called Apoptotic DNA Immunotherapy (ADi) ADI-100, which utilizes a novel approach that mimics, the way bodies naturally induce tolerance to tissues.
About PRFX PainReform Ltd.
PainReform Ltd is a clinical-stage specialty pharmaceutical company. It is focused on the reformulation of established therapeutics. The company's product PRF-110 is based on the local anesthetic ropivacaine, targeting the post-operative pain relief market. PRF-110 is an oil-based, viscous, clear solution that is deposited directly into the surgical wound bed before closure to provide localized and extended post-operative analgesia.